Recent Updates
Recently added Catalysts

Cetirizine Dry Syrup

Phase 3

Dermatitis, Atopic | Small molecule | Dermatology |GSK plc|Last Updated: May 6, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment278

FDA Designations

No designations recorded

Clinical trial landscape

Cetirizine Dry Syrup · 4 trials · 3 indications

Phase 3 4
NCT00257569Study Of Atopic Dermatitis In PediatricsDermatitis, Atopic
COMPLETED278 Analytics
NCT00257582Study Of Cutaneous Disease Accompanied With Pruritus In PediatricsPruritus
COMPLETED60 Analytics
NCT00257595Perennial Allergic Rhinitis In Pediatric SubjectsRhinitis, Allergic, Perennial
COMPLETED30 Analytics
NCT00253058Study Of Perennial Allergic Rhinitis In PediatricsRhinitis, Allergic, Perennial
COMPLETED286 Analytics
PHASE3COMPLETED
Study Of Atopic Dermatitis In Pediatrics
Dermatitis, Atopic
NCT00257569278
Unlock trial analytics
PHASE3COMPLETED
Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics
Pruritus
NCT0025758260
Unlock trial analytics
PHASE3COMPLETED
Perennial Allergic Rhinitis In Pediatric Subjects
Rhinitis, Allergic, Perennial
NCT0025759530
Unlock trial analytics
PHASE3COMPLETED
Study Of Perennial Allergic Rhinitis In Pediatrics
Rhinitis, Allergic, Perennial
NCT00253058286
Unlock trial analytics

Study Endpoints

Primary Endpoints

change in the severity of pruritus
To assess the safety
safety
change in the total nasal symptom score (TNSS)

Secondary Endpoints

-changes in the total pruritus score -daily main pruritus score -improvement of area with pruritus -patient global improvement -Cetirizine serum concentrations -Adverse events
-severity of pruritus -total pruritus score -daily main prurutus score -Severity of eruption -Patient global Improvement rating -Body temperature -Adverse events -Cetirizine serum concentrations
Total Nasal Symptom Score (TNSS) Individual nasal symptom score total score of 4 individual daily symptom scores Investigator global improvement rating
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
Cetirizine Dry SyrupDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range3 Years to 14 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Children diagnosed as atopic dermatitis * Giving informed consent * Children who have 2 grades or more pruritus score. * Children who require the treatment with external steroid preparation other than face and head. * Children with a pruritus severity of 2. * Mild or severe on...

Countries:
Unlock Eligibility Criteria